Astrazeneca Rises 1.23% as Respiratory Drug Trials Push Stock to 365th in Daily Trading Volume

Astrazeneca (AZN) rose 1.23% on August 20, 2025, with a trading volume of $0.29 billion, ranking 365th among listed stocks. The pharmaceutical giant is advancing two key clinical trials that could bolster its respiratory treatment pipeline. A Phase I study for inhaled AZD8630 in adolescent asthma patients is evaluating pharmacokinetics, safety, and inhaler performance, while a Phase 2a trial for oral Atuliflapon targets adults with uncontrolled asthma. Both studies highlight the company’s focus on addressing unmet medical needs in respiratory diseases through innovative therapies.

The AZD8630 trial employs a dry powder inhaler to assess single-dose effects, emphasizing delivery system efficacy. Meanwhile, Atuliflapon’s randomized, double-blind design aims to validate its potential as a daily oral treatment for patients inadequately managed by existing therapies. These developments underscore Astrazeneca’s strategic emphasis on respiratory innovation, a sector with high commercial and therapeutic value. Positive outcomes could differentiate the company in a competitive market, potentially enhancing investor confidence.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The total profit grew steadily over the past year, with a few fluctuations. As of the latest data, the strategy's profit reached $2,385.14.